Editas Medicine (EDIT) Tops Q3 EPS by 25c; Cash and Cash Equivalents of $657.0M

Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.57), $0.25 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $4.78 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Morgan Stanley Downgrades Peloton Interactive (PTON) to Underweight
• JPMorgan Upgrades Yangzijiang Shipbuilding (YZJSGD:SP) (YSHLF) to Overweight